JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v133,p864)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Carolyn E. Reed
David H. Harpole
Robert J. Downey
Bryan F. Meyers
Valerie W. Rusch
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reed, C. E.
Right arrow Articles by Rusch, V. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reed, C. E.
Right arrow Articles by Rusch, V. W.
Related Collections
Right arrow Lung - cancer

J Thorac Cardiovasc Surg 2003;126:1943-1951
© 2003 The American Association for Thoracic Surgery


General thoracic surgery

Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer

Carolyn E. Reed, MDa,*, David H. Harpole, MDb, Katherine E. Posther, MDc, Sandra L. Woolson, MPhd, Robert J. Downey, MDe, Bryan F. Meyers, MDf, Robert T. Heelan, MDg, Homer A. MacApinlac, MDh, Sin-Ho Jung, PhDi, Gerard A. Silvestri, MDj, Barry A. Siegel, MDk, Valerie W. Rusch, MDl

a Hollings Cancer Center, Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, USA
b Thoracic Oncology Program, Duke Comprehensive Cancer Center, Durham, NC, USA
c Department of Surgery, Duke University Medical Center, Durham, NC, USA
d Department of Biostatistics, Duke University Medical Center, Durham, NC, USA
e Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
f Division of Cardiothoracic Surgery, Washington University School of Medicine, St Louis, Mo, USA
g Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
h Department of Nuclear Medicine, MD Anderson Cancer Center, Houston, Tex, USA
i Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA
j Division of Pulmonary Medicine, Medical University of South Carolina, Charleston, SC, USA
k Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Mo, USA
l Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.

Received for publication April 29, 2003; revisions received July 25, 2003; accepted for publication July 30, 2003.

* Address for reprints: Carolyn E. Reed, MD, Hollings Cancer Center, 86 Jonathan Lucas Street, Charleston, SC 29425, USA
reedce{at}musc.edu

OBJECTIVES: The American College of Surgeons Oncology Group undertook a trial to ascertain whether positron emission tomography with 18F-fluorodeoxyglucose could detect lesions that would preclude pulmonary resection in a group of patients with documented or suspected non–small cell lung cancer found to be surgical candidates by routine staging procedures.

METHODS: A total of 303 eligible patients registered from 22 institutions underwent positron emission tomography after routine staging (computed tomography of chest and upper abdomen, bone scintigraphy, and brain imaging) had deemed their tumors resectable. Positive findings required confirmatory procedures.

RESULTS: Positron emission tomography was significantly better than computed tomography for the detection of N1 and N2/N3 disease (42% vs 13%, P = .0177, and 58% vs 32%, P = .0041, respectively). The negative predictive value of positron emission tomography for mediastinal node disease was 87%. Unsuspected metastatic disease or second primary malignancy was identified in 18 of 287 patients (6.3%). Distant metastatic disease indicated in 19 of 287 patients (6.6%) was subsequently shown to be benign. By correctly identifying advanced disease (stages IIIA, IIIB, and IV) or benign lesions, positron emission tomography potentially avoided unnecessary thoracotomy in 1 of 5 patients.

CONCLUSIONS: In patients with suspected or proven non–small cell lung cancer considered resectable by standard staging procedures, positron emission tomography can prevent nontherapeutic thoracotomy in a significant number of cases. Use of positron emission tomography for mediastinal staging should not be relied on as a sole staging modality, and positive findings should be confirmed by mediastinoscopy. Metastatic disease, especially a single site, identified by positron emission tomography requires further confirmatory evaluation.





This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
D. L. Schwartz, H. A. Macapinlac, and R. S. Weber
FDG-PET Staging of Head and Neck Cancer--Can Improved Imaging Lead to Improved Treatment?
J Natl Cancer Inst, May 21, 2008; 100(10): 688 - 689.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. D. Kozower, B. F. Meyers, C. E. Reed, D. R. Jones, P. A. Decker, and J. B. Putnam Jr
Does Positron Emission Tomography Prevent Nontherapeutic Pulmonary Resections for Clinical Stage IA Lung Cancer?
Ann. Thorac. Surg., April 1, 2008; 85(4): 1166 - 1170.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
G A Silvestri and S G Spiro
Carcinoma of the bronchus 60 years later
Postgrad. Med. J., April 1, 2008; 84(990): 182 - 187.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
H. Melek, M. Z. Gunluoglu, A. Demir, H. Akin, A. Olcmen, and S. I. Dincer
Role of positron emission tomography in mediastinal lymphatic staging of non-small cell lung cancer
Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 294 - 299.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
N. Al-Sarraf, R. Aziz, K. Gately, J. Lucey, L. Wilson, E. McGovern, and V. Young
Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography
Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 104 - 109.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
Y. C. Ung, D. E. Maziak, J. A. Vanderveen, C. A. Smith, K. Gulenchyn, C. Lacchetti, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta
18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review
J Natl Cancer Inst, December 5, 2007; 99(23): 1753 - 1767.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. F. Ismail
Sentinel node sampling in stage I non-small cell lung cancer
Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 948 - 949.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. J. Cerfolio and A. S. Bryant
When is it Best to Repeat a 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant Chemoradiotherapy?
Ann. Thorac. Surg., October 1, 2007; 84(4): 1092 - 1097.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. McCrory, E. Toloza, and F. Detterbeck
Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 178S - 201S.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
F. C Detterbeck
Evolution and science, progress and change
Thorax, August 1, 2007; 62(8): 654 - 655.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
P. C. Lee, J. L. Port, R. J. Korst, Y. Liss, D. N. Meherally, and N. K. Altorki
Risk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer
Ann. Thorac. Surg., July 1, 2007; 84(1): 177 - 181.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. J. Cerfolio and A. S. Bryant
Predictors of Survival and Disease-Free Survival in Patients With Resected N1 Non-Small Cell Lung Cancer
Ann. Thorac. Surg., July 1, 2007; 84(1): 182 - 190.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
Notice of Correction: Results of ACOSOG Z0050 trial: The utility of FDG-PET in staging potentially operable non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., April 1, 2007; 133(4): 864 - 864.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
B. E. Lee, D. von Haag, T. Lown, D. Lau, R. Calhoun, and D. Follette
Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer
J. Thorac. Cardiovasc. Surg., March 1, 2007; 133(3): 746 - 752.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. S. Bryant and R. J. Cerfolio
The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers
J. Thorac. Cardiovasc. Surg., December 1, 2006; 132(6): 1363 - 1368.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
G A Silvestri and S G Spiro
Carcinoma of the bronchus 60 years later.
Thorax, December 1, 2006; 61(12): 1023 - 1028.
[Full Text] [PDF]


Home page
JNMHome page
K. E. Posther, L. M. McCall, D. H. Harpole Jr., C. E. Reed, J. B. Putnam Jr., V. W. Rusch, and B. A. Siegel
Yield of Brain 18F-FDG PET in Evaluating Patients with Potentially Operable Non-Small Cell Lung Cancer
J. Nucl. Med., October 1, 2006; 47(10): 1607 - 1611.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. Fujimoto, S. D. Cassivi, P. Yang, S. A. Barnes, F. C. Nichols, C. Deschamps, M. S. Allen, and P. C. Pairolero
Completely resected N1 non-small cell lung cancer: Factors affecting recurrence and long-term survival.
J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 499 - 506.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
J. A. Carr and J. M. Silver
The false assumption of lung cancer based upon a positive positron emission tomographic scan
Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 446 - 447.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
C. Schimmer, K. Neukam, and O. Elert
Staging of non-small cell lung cancer: clinical value of positron emission tomography and mediastinoscopy
Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 418 - 423.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
O. Mawlawi, J. J. Erasmus, T. Pan, D. D. Cody, R. Campbell, A. H. Lonn, S. Kohlmyer, H. A. Macapinlac, and D. A. Podoloff
Truncation Artifact on PET/CT: Impact on Measurements of Activity Concentration and Assessment of a Correction Algorithm.
Am. J. Roentgenol., May 1, 2006; 186(5): 1458 - 1467.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. J.M. Herder, H. Kramer, O. S. Hoekstra, E. F. Smit, J. Pruim, H. van Tinteren, E. F. Comans, P. Verboom, C. A. Uyl-de Groot, A. Welling, et al.
Traditional Versus Up-Front [18F] Fluorodeoxyglucose-Positron Emission Tomography Staging of Non-Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study
J. Clin. Oncol., April 20, 2006; 24(12): 1800 - 1806.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Lardinois
New Horizons in Staging for Non-Small-Cell Lung Cancer
J. Clin. Oncol., April 20, 2006; 24(12): 1785 - 1787.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
B. F. Meyers, F. Haddad, B. A. Siegel, J. B. Zoole, R. J. Battafarano, N. Veeramachaneni, J. D. Cooper, and G. A. Patterson
Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer
J. Thorac. Cardiovasc. Surg., April 1, 2006; 131(4): 822 - 829.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
J. L. Port, R. S. Andrade, M. A. Levin, R. J. Korst, P. C. Lee, D. E. Becker, and N. K. Altorki
Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less
J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1611 - 1615.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
V. W. Rusch
Mediastinoscopy: An Endangered Species?
J. Clin. Oncol., November 20, 2005; 23(33): 8283 - 8285.
[Full Text] [PDF]


Home page
JCOHome page
F. Pozo-Rodriguez, J. L. Martin de Nicolas, M. A. Sanchez-Nistal, A. Maldonado, S. Garcia de Barajas, R. Calero-Garcia, M. A. Pozo, P. Martin-Escribano, I. Martin-Garcia, R. Garcia-Lujan, et al.
Accuracy of Helical Computed Tomography and [18F] Fluorodeoxyglucose Positron Emission Tomography for Identifying Lymph Node Mediastinal Metastases in Potentially Resectable Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2005; 23(33): 8348 - 8356.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
V. Patel and J. B. Shrager
Which Patients with Stage III Non-Small Cell Lung Cancer Should Undergo Surgical Resection?
Oncologist, May 1, 2005; 10(5): 335 - 344.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
L. Schrevens, N. Lorent, C. Dooms, and J. Vansteenkiste
The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer
Oncologist, November 1, 2004; 9(6): 633 - 643.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. J. Downey, T. Akhurst, M. Gonen, A. Vincent, M. S. Bains, S. Larson, and V. Rusch
Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection
J. Clin. Oncol., August 15, 2004; 22(16): 3255 - 3260.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
F. C. Detterbeck, S. Falen, M. P. Rivera, J. S. Halle, and M. A. Socinski
Seeking a Home for a PET, Part 2: Defining the Appropriate Place for Positron Emission Tomography Imaging in the Staging of Patients With Suspected Lung Cancer
Chest, June 1, 2004; 125(6): 2300 - 2308.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.